消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

《2021年亚太肝病学会慢性乙型肝炎患者停用核苷（酸）类似物指导意见》摘译

2022-01-15 首都医科大学附属北京佑安医院肝病中心一科 临床肝胆病杂志

慢性乙型肝炎核酸类似物

HBV感染目前无法完全根治,强效、安全的核苷（酸）类似物[nucleos（t）ide analog, NUC]长期治疗可通过显著抑制病毒复制,减少肝硬化及相关并发症和肝细胞癌（HCC）的发生,但长期治

中文标题：

《2021年亚太肝病学会慢性乙型肝炎患者停用核苷（酸）类似物指导意见》摘译

发布机构：

首都医科大学附属北京佑安医院肝病中心一科

发布日期：

2022-01-15

简要介绍：

HBV感染目前无法完全根治,强效、安全的核苷（酸）类似物[nucleos（t）ide analog, NUC]长期治疗可通过显著抑制病毒复制,减少肝硬化及相关并发症和肝细胞癌（HCC）的发生,但长期治疗有利有弊。由于NUC抑制病毒作用强、口服方便、耐受性好、不良反应少且轻微等优点,临床应用普遍。但NUC不能完全清除肝细胞内共价闭合环状DNA（cccDNA）,难以获得HBsAg清除,HBsAg年转阴率仅为0.15%～0.33%。

相关资料下载：
[AttachmentFileName(sort=1, fileName=《2021年亚太肝病学会慢性乙型肝炎患者停用核苷（酸）类似物指导意见》摘译.pdf)] GetToolGuiderByIdResponse(projectId=1, id=969191c00238e142, title=《2021年亚太肝病学会慢性乙型肝炎患者停用核苷（酸）类似物指导意见》摘译, enTitle=, guiderFrom=临床肝胆病杂志, authorId=0, author=, summary=HBV感染目前无法完全根治,强效、安全的核苷（酸）类似物[nucleos（t）ide analog, NUC]长期治疗可通过显著抑制病毒复制,减少肝硬化及相关并发症和肝细胞癌（HCC）的发生,但长期治, cover=https://img.medsci.cn/2022320/1647752622275_5579292.jpg, journalId=0, articlesId=null, associationId=2539, associationName=首都医科大学附属北京佑安医院肝病中心一科, associationIntro=首都医科大学附属北京佑安医院肝病中心一科, copyright=0, guiderPublishedTime=Sat Jan 15 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #666666;">HBV感染目前无法完全根治,强效、安全的核苷（酸）类似物[nucleos（t）ide analog, NUC]长期治疗可通过显著抑制病毒复制,减少肝硬化及相关并发症和肝细胞癌（HCC）的发生,但长期治疗有利有弊。由于NUC抑制病毒作用强、口服方便、耐受性好、不良反应少且轻微等优点,临床应用普遍。但NUC不能完全清除肝细胞内共价闭合环状DNA（cccDNA）,难以获得HBsAg清除,HBsAg年转阴率仅为0.15%～0.33%。</span></p>, tagList=[TagDto(tagId=2629, tagName=慢性乙型肝炎), TagDto(tagId=107879, tagName=核酸类似物)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=9, categoryName=传染科, tenant=100), CategoryDto(categoryId=22, categoryName=肝病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5462, appHits=133, showAppHits=0, pcHits=223, showPcHits=5329, likes=2, shares=25, comments=4, approvalStatus=1, publishedTime=Sun Mar 20 15:31:00 CST 2022, publishedTimeString=2022-01-15, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Sun Mar 20 13:01:49 CST 2022, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sun Dec 31 22:02:13 CST 2023, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=《2021年亚太肝病学会慢性乙型肝炎患者停用核苷（酸）类似物指导意见》摘译.pdf)])
《2021年亚太肝病学会慢性乙型肝炎患者停用核苷（酸）类似物指导意见》摘译.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1204837, encodeId=0141120483e77, content=谢谢！学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=936e6556711, createdName=ms7000000490578574, createdTime=Tue Mar 22 08:58:07 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204701, encodeId=05401204e0148, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdd51992964, createdName=1e1ac4a1m23(暂无匿称), createdTime=Mon Mar 21 19:40:09 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204360, encodeId=a7a7120436043, content=停药复发加重病情, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210120/778f7c357edd473a84d5ea9bc71bb3c0/b2f769fd238c495399c56c6b92326c43.jpg, createdBy=19dd2038264, createdName=碧水流芳, createdTime=Sun Mar 20 15:46:08 CST 2022, time=2022-03-20, status=1, ipAttribution=)]
    2022-03-22 ms7000000490578574

    谢谢！学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1204837, encodeId=0141120483e77, content=谢谢！学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=936e6556711, createdName=ms7000000490578574, createdTime=Tue Mar 22 08:58:07 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204701, encodeId=05401204e0148, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdd51992964, createdName=1e1ac4a1m23(暂无匿称), createdTime=Mon Mar 21 19:40:09 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204360, encodeId=a7a7120436043, content=停药复发加重病情, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210120/778f7c357edd473a84d5ea9bc71bb3c0/b2f769fd238c495399c56c6b92326c43.jpg, createdBy=19dd2038264, createdName=碧水流芳, createdTime=Sun Mar 20 15:46:08 CST 2022, time=2022-03-20, status=1, ipAttribution=)]
    2022-03-21 1e1ac4a1m23(暂无匿称)

    好资料

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1204837, encodeId=0141120483e77, content=谢谢！学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=936e6556711, createdName=ms7000000490578574, createdTime=Tue Mar 22 08:58:07 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204701, encodeId=05401204e0148, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdd51992964, createdName=1e1ac4a1m23(暂无匿称), createdTime=Mon Mar 21 19:40:09 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204360, encodeId=a7a7120436043, content=停药复发加重病情, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210120/778f7c357edd473a84d5ea9bc71bb3c0/b2f769fd238c495399c56c6b92326c43.jpg, createdBy=19dd2038264, createdName=碧水流芳, createdTime=Sun Mar 20 15:46:08 CST 2022, time=2022-03-20, status=1, ipAttribution=)]
    2022-03-20 碧水流芳

    停药复发加重病情

    0

相关指南

国内外慢性乙型肝炎管理指南推荐建议的比较

首都医科大学附属北京天坛医院药学部 · 2021-07-07

《APASL慢性乙型肝炎患者停用核苷(酸)类似物指导意见》解读

国家重大公共卫生事件医学中心华中科技大学同济医学院附属同济医院感染科 · 2021-10-20

2021 APASL指南：慢性乙型肝炎患者停用核苷（酸）类似物

亚太肝脏研究学会(APASL,Asian-Pacific Association for the Study of the Liver) · 2021-08-15

慢性乙型肝炎防治指南（2019年版）

中华医学会肝病学分会(Chinese Society of Hepatology, CMA) · 2020-01-03

慢性乙型肝炎基层诊疗指南（2020年）

中华医学会(CMA,Chinese Medical Association) · 2021-02-20

慢性乙型肝炎基层诊疗指南（实践版·2020）

中华医学会(CMA,Chinese Medical Association) · 2021-03-25